We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
According to Rwanda's Ministry of Health, the country was able to supply approximately 3,200 people with antiretroviral (ARV) drugs in 2006, representing 1.6 percent of the people who needed the medication, local newspaper The New Times reports.
British drugmaker GlaxoSmithKline (GSK) has begun a study designed to compare the immunogenicity of its experimental cervical cancer vaccine, Cervarix, with Merck's Gardasil.
In response to media reports that Japanese drugmakers Tanabe Seiyaku and Mitsubishi Pharma are considering a merger, Tanabe issued a press release today saying, "Tanabe has been discussing with Mitsubishi Pharma on a potential merger between the two companies for the purpose of expansion of business scale and reinforcement of management infrastructure to respond to the competitive environment surrounding the pharmaceutical market and survive intensifying global competition.
In a report titled "Children and AIDS: A Stocktaking," the United Nations Children's Fund (UNICEF) stressed that further action needs to be taken to prevent mother-to-child HIV transmission and to treat children with HIV.
Biovail announced that its marketing partner GlaxoSmithKline (GSK) has been granted approval to market Wellbutrin XR (bupropion hydrochloride modified-release tablets) for treating adult patients with major depressive episodes in the Netherlands.
Peregrine Pharmaceuticals announced that its partner Shanghai Medipharm Biotech has launched an iodine-131 radiolabeled Tumor Necrosis Therapy (TNT) antibody for the treatment of lung cancer.
The government of Zimbabwe is planning to triple the number of people enrolled in its free antiretroviral (ARV) treatment program in 2007, but activists are skeptical about the country's ability to meet this goal, the UN Integrated Regional Information Networks (IRIN) reports.
The FDA wants to prohibit certain cattle material from drugs, biologics and medical devices to lower the risk of bovine spongiform encephalopathy (BSE or mad cow disease.)